GlassScriptPhysician profile
Jonathan Church
NPI 1598152217
$45,233.00
in general payments reported to CMS, 2019-2025
46 companies · $2,562 in 2025
The $2,562 reported for 2025 was more than what 86% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $3,132 · 2021: $4,795 · 2022: $4,775 · 2023: $5,615 · 2024: $4,439 · 2025: $2,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Travel and Lodging: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,445.21 |
| Travel and Lodging | $171.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $15,818.75 | 2019-2020 | |
| Abbott Laboratories | $15,584.22 | 2019-2025 | Proclaim, Eterna |
| Nevro Corp. | $3,469.57 | 2019-2024 | Senza |
| Medtronic, INC. | $1,827.04 | 2022-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Boston Scientific Corporation | $1,730.55 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Relievant Medsystems, INC. | $1,134.86 | 2021-2023 | Intracept |
| Abbvie INC. | $577.91 | 2021-2025 | Ubrelvy, Qulipta |
| Merz North America, INC. | $560.76 | 2023 | Xeomin |
| Tersera Therapeutics LLC | $426.57 | 2019-2024 | Prialt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $364.81 | 2019-2025 | Relistor |
| Spinal Simplicity, LLC | $348.48 | 2024-2025 | Ha Minuteman G3-R |
| Foundation Fusion Solutions, LLC | $270.20 | 2021 | |
| Globus Medical, INC. | $245.89 | 2025 | Senza |
| Collegium Pharmaceutical, INC. | $240.81 | 2020-2025 | Belbuca, Xtampza |
| Vertiflex, INC. | $237.40 | 2019 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $205.88 | 2021-2024 | Nalu Neurostimulation System |
| Curonix LLC | $205.14 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Vertos Medical, INC. | $160.73 | 2022-2024 | Mild Device Kit |
| Pfizer INC. | $156.28 | 2020-2025 | |
| Depuy Synthes Sales INC. | $145.66 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $140.72 | 2020-2024 | Ztlido |
| Davol INC. | $127.96 | 2024 | Phasix Mesh |
| Saluda Medical Americas, INC. | $120.07 | 2025 | Evoke |
| Biotronik Nro, INC. | $109.32 | 2025 | Prospera |
| Flowonix Medical Incorporated | $90.15 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $83.56 | 2020-2021 | |
| Stryker Corporation | $78.57 | 2024-2025 | Mild Device Kit |
| Si-Bone, INC. | $77.78 | 2025 | |
| Amgen INC. | $66.30 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $66.29 | 2020-2022 | |
| Biodelivery Sciences International, INC. | $65.01 | 2021 | |
| Allergan, INC. | $60.36 | 2020 | |
| Impel Pharmaceuticals INC. | $54.68 | 2023 | Trudhesa |
| Protega Pharmaceutials INC | $49.85 | 2025 | Roxybond |
| Forte Bio-Pharma LLC | $49.50 | 2021 | |
| Arbor Pharmaceuticals, INC. | $40.14 | 2020-2021 | |
| Spr Therapeutics, INC | $36.59 | 2025 | Sprint Pns System |
| Biohaven Pharmaceutical Holding Company LTD. | $32.64 | 2022 | |
| Convatec INC. | $32.37 | 2024-2025 | |
| Zimmer Biomet Holdings, INC. | $26.46 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Averitas Pharma INC. | $24.77 | 2023 | Qutenza |
| Spinefrontier, INC. | $20.23 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $19.49 | 2024 | Crysvita |
| Zyla Life Sciences, INC. | $19.05 | 2020 | |
| Grt US Holding, INC. | $18.14 | 2021 | |
| Almatica Pharma LLC | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Church listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.